These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7739293)

  • 21. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel anticancer drug discovery.
    Buolamwini JK
    Curr Opin Chem Biol; 1999 Aug; 3(4):500-9. PubMed ID: 10419854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent progress in fungus-derived bioactive agents for targeting of signaling machinery in cancer cells.
    Lin X; Farooqi AA; Ismail M
    Drug Des Devel Ther; 2015; 9():1797-804. PubMed ID: 25848216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogene signal transduction inhibitors from medicinal plants.
    Chang CJ; Ashendel CL; Geahlen RL; McLaughlin JL; Waters DJ
    In Vivo; 1996; 10(2):185-90. PubMed ID: 8744799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals.
    Kadioglu O; Cao J; Saeed ME; Greten HJ; Efferth T
    Target Oncol; 2015 Sep; 10(3):337-53. PubMed ID: 25410594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth factors and cancer.
    Aaronson SA
    Science; 1991 Nov; 254(5035):1146-53. PubMed ID: 1659742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenes and cancer suppressor genes.
    Yarbro JW
    Semin Oncol Nurs; 1992 Feb; 8(1):30-9. PubMed ID: 1546217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.
    Zhang Z; Li M; Rayburn ER; Hill DL; Zhang R; Wang H
    Am J Pharmacogenomics; 2005; 5(4):247-57. PubMed ID: 16078861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of the signal transduction program by drugs.
    Weber G; Shen F; Prajda N; Yang H; Li W; Yeh A; Csokay B; Olah E; Look KY
    Adv Enzyme Regul; 1997; 37():35-55. PubMed ID: 9381980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
    Buettner R; Mora LB; Jove R
    Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
    Klener P; Klener P
    Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic targets in the ARF tumor suppressor pathway.
    Saporita AJ; Maggi LB; Apicelli AJ; Weber JD
    Curr Med Chem; 2007; 14(17):1815-27. PubMed ID: 17627519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The biology of signal transduction inhibition: basic science to novel therapies.
    Griffin J
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for inhibiting multistage carcinogenesis based on signal transduction pathways.
    Weinstein IB
    Mutat Res; 1988 Dec; 202(2):413-20. PubMed ID: 3057370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.